medigraphic.com

2012, Number 1

<< Back Next >>

Rev Cuba Endoc 2012; 23 (1)

The ruboxistaurin, an alternative in the diabetic macular edema

Pérez MME, Maciques RJE

Language: Spanish
References: 18
Page:
PDF size: 51.49 Kb.


ABSTRACT

Backgrounds: the macular edema is the main cause of low vision in persons with diabetic retinopathy.
Objective: to analyze the results of treatment with ruboxistaurin in cases of diabetic macular edema.
Development: the hyperglycemia among other metabolic alterations, to active the kinase C protein contributing to microvascular dysfunction, an important disorder in the pathogenesis of the diabetic macular edema. Different therapeutical procedures have been used in its treatment. In past years the ruboxistaurin has showed its ability to inhibit the activation of C kinase protein. Some authors consider that this drug is able to improve the diabetic macular edema and thus, the vision. It has been reported that the administration of 32 mg daily de ruboxistaurin prevents the progression of the diabetic retinopathy and decrease the risk of visual loss from diabetic macular edema. Other studies describe similar results and also, report that this drug decreases the risk or worsening and progression of this type of edema as well as to reduce the need of laser treatment.
Conclusions: the use of ruboxistaurin open new perspectives for prevention and treatment of visual deficit due to diabetic retinopathy and from the diabetic macular edema, however, authors consider that the studies conducted until now are insufficient to arrive to valid conclusions. Studies at longer term are necessary to define its cost/benefit.


REFERENCES

  1. Golbidi S, Ebadi SA, Laher I. Antioxidantes en el tratamiento de la diabetes. Revolución de la Diabetes. De Curr. 2011;7:106-25.

  2. Romero M, Almena M, Baget I, Méndez M. Actualización en la epidemiología del edema macular diabético. Annals d'Oftalmologia. 2005;13:92-102.

  3. Pareja A, Serrano MA, Marrero MD, Abraldes VM, Reyes MA, Cabrera F, et al. Guías de práctica clínica de la SERV: manejo de las complicaciones oculares de la diabetes. retinopatía diabética y edema macular. Arch Soc Esp Oftalmol. 2009;84:429-50.

  4. Ramírez JA, Levine A, Rojas S, Celis B, García R, Rentería H. Vitrectomía más triamcinolona transoperatoria para el edema macular diabético con exudados duros. Rev Mex Oftalmol. 2006;80:112-5.

  5. Arevalo JF. Results from the Pan-American Collaborative Retina Study Group. PACRS. Ophthalmology. 2007;114:743-50.

  6. Mesa GJ, Porta MI, Cabiró BV, Amías LA, Rouras L. Protocolos de tratamiento de la maculopatia diabética. Annals d'Oftalmologia. 2010;18:86-91.

  7. Galvez MI. Protein kinase C inhibitors in the treatment of diabetic retinopathy. Rev Curr Pharm Biotechnol. 2011;12:386-91.

  8. Moreno J, Palomares R, Benito P. Nuevos tratamientos en la diabetes mellitus. En: Gomis de Barbará R, Rovira A, Felíu JE, Oyarzabal M (eds.). Tratado SED de diabetes mellitus. Bases moleculares, clínicas y tratamiento. Madrid: Ed. Panamericana; 2007. p. 331-40.

  9. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res. 2004;28:251-6.

  10. Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B. Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol. 2010;10:1552-9.

  11. 11 Antonetti DA, Barber AJ, Bronson SK. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401-11.

  12. Davis MD, Sheetz MJ, Aiello LP. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:1-4.

  13. Aiello LP, Bursell SE, Devries T, Alatorre C, King GL, Ways DK. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86-92.

  14. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the PKC-DRS multicenter randomized clinical trial. Diabetes. 2005;54:2186-97.

  15. The PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-30.

  16. Aiello LP, Davis MD, Girach A, Hu K, Milton RC, et al. Effect of Ruboxistaurin in Patients with Diabetic Macular Edema: Thirty-Month Results of the Randomized PKC-DMES Clinical Trial. Arch Ophthalmol. 2007;125:318-24.

  17. Claramunt lJ. Retinopatía diabética. Rev Med Clin Condes. 2009;20:670-9.

  18. Sheetz MJ, Aiello LP, Shahri N, Davis MDFONT C Kles KA, Danis RP; for the Mbdv Study Group. Effect of Ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina. 2011;31:1053-9.




2020     |     www.medigraphic.com